Table 3.
Change from baseline in difficulty in swallowinga and sore throat reliefb at the end of day 1, at 24 hours post-first dose, and at the end of days 2 and 3; intent-to-treat population
| Difficulty in swallowing | Sore throat relief | |||||
|---|---|---|---|---|---|---|
| Difference between least squares meansc | 95% CI | P-value for treatment | Difference between least squares meansa | 95% CI | P-value for treatment | |
| End of day 1 | –5.55 | –10.15 to –0.94 | 0.018 | 0.42 | 0.05 to 0.80 | 0.026 |
| 24 hours post-first dose | –4.31 | –8.79 to 0.16 | 0.059 | 0.28 | –0.10 to 0.66 | 0.150 |
| End of day 2 | –5.74 | –10.39 to –1.09 | 0.016 | 0.33 | –0.06 to 0.73 | 0.101 |
| End of day 3 | –5.12 | –9.80 to –0.43 | 0.032 | 0.38 | –0.04 to 0.79 | 0.078 |
Measured on 100 mm visual analogue scale where 0 mm = no difficulty, 100 mm = very difficult.
Measured on a 7-point scale where 0 = no relief, 6 = complete relief.
Flurbiprofen 8.75 mg microgranules minus placebo.